ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (3): 93-97.doi: 10.6040/j.issn.1673-3770.0.2022.044
• 论著 • Previous Articles
ZHANG Yi, TANG Li
CLC Number:
| [1] Lowe CU, Terrey M, MacLachlan EA. Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation; a clinical entity[J]. AMA Am J Dis Child, 1952, 83(2): 164-184. doi:10.1001/archpedi.1952.02040060030004 [2] 高珊,李晶晶,林俊.儿童Lowe综合征2例报告[J].四川大学学报(医学版),2019,50(1):144. doi:10.13464/j.scuxbyxb.2019.01.035 [3] 张晓滢,孙良忠,刘婷,等. 六个Lowe综合征家系七例患儿的临床特征与OCRL1基因突变[J].中华肾脏病杂志, 2020, 36(5):372-378. doi:10.3760/cma.j.cn441217-20191115-00071 ZHANG Xiaoying, SUN Liangzhong, LIU Ting, et al. Clinical features of Lowe syndrome and OCRL1 mutations in seven cases from six families[J]. Chin J Nephrol, 2020, 36(5): 372-378. doi:10.3760/cma.j.cn441217-20191115-00071 [4] Lin T, Orrison BM, Leahey AM, et al. Spectrum of mutations in the OCRL1 gene in the Lowe oculocerebrorenal syndrome[J]. Am J Hum Genet, 1997, 60(6): 1384-1388. doi:10.1086/515471 [5] 张永玲, 李茹, 景象一, 等. 一例Lowe综合征患儿的临床及分子遗传学诊断[J]. 中华医学遗传学杂志, 2019, 36(6): 613-615. doi:10.3760/cma.j.issn.1003-9406.2019.06.021 ZHANG Yongling, LI Ru, JING Xiangyi, et al. Clinical and molecular genetic analysis of a pediatric patient with Lowe syndrome[J]. Chinese Journal of Medical Genetics, 2019, 36(6): 613-615. doi:10.3760/cma.j.issn.1003-9406.2019.06.021 [6] 白周现, 刘莉娜, 胡爽, 等. 一例OCRL基因外显子重复变异所致的眼脑肾综合征患儿的临床及遗传学分析[J]. 中华医学遗传学杂志, 2020, 37(1): 28-32. doi:10.3760/cma.j.issn.1003-9406.2020.01.008 BAI Zhouxian, LIU Lina, HU Shuang, et al. Clinical and genetic analysis of an infant with Lowe syndrome caused by exonic duplication of OCRL gene[J]. Chinese Journal of Medical Genetics, 2020, 37(1): 28-32. doi:10.3760/cma.j.issn.1003-9406.2020.01.008 [7] Tatsi P, Papanikolaou GE, Chartomatsidou T, et al. Lowe syndrome identified in the offspring of an oocyte donor who was an unknown carrier of a de novo mutation: a case report and review of the literature[J]. J Med Case Rep, 2019, 13(1): 325. doi:10.1186/s13256-019-2263-9 [8] Zhou FQ, Wang QW, Liu ZZ, et al. Novel mutation in OCRL leading to a severe form of Lowe syndrome[J]. Int J Ophthalmol, 2019, 12(7): 1057-1060. doi:10.18240/ijo.2019.07.01 [9] Bökenkamp A, Ludwig M. The oculocerebrorenal syndrome of Lowe: an update[J]. Pediatr Nephrol, 2016, 31(12): 2201-2212. doi:10.1007/s00467-016-3343-3 [10] Sun J, Zhou Z, Weng C, et al. Identification and functional characterization of a hemizygous novel intronic variant in OCRL gene causes Lowe syndrome[J]. Clin Exp Nephrol, 2020, 24(8): 657-665. doi:10.1007/s10157-020-01897-6 [11] Ramadesikan S, Skiba L, Lee J, et al. Genotype & phenotype in Lowe Syndrome: specific OCRL1 patient mutations differentially impact cellular phenotypes[J]. Hum Mol Genet, 2021, 30(3/4): 198-212. doi:10.1093/hmg/ddab025 [12] Ramos AR, Ghosh S, Erneux C. The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease[J]. J Lipid Res, 2019, 60(2): 276-286. doi:10.1194/jlr.r087908 [13] Madhivanan K, Ramadesikan S, Hsieh WC, et al. Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins[J]. Hum Mol Genet, 2020, 29(10): 1700-1715. doi:10.1093/hmg/ddaa086 [14] Dumic KK, Anticevic D, Petrinovic-Doresic J, et al. Lowe syndrome-Old and new evidence of secondary mitochondrial dysfunction[J]. Eur J Med Genet, 2020, 63(10): 104022. doi:10.1016/j.ejmg.2020.104022 [15] Mehta ZB, Pietka G, Lowe M. The cellular and physiological functions of the Lowe syndrome protein OCRL1[J]. Traffic, 2014, 15(5): 471-487. doi:10.1111/tra.12160 [16] Daskalakis G, Anastasakis E, Lyberopoulos E, et al. Prenatal detection of congenital cataract in a fetus with Lowe syndrome[J]. J Obstet Gynaecol, 2010, 30(4): 409-410. doi:10.3109/01443611003698695 [17] 谭健文, 赖一凡. Lowe综合征的眼部表现及其诊治[J]. 国际眼科纵览, 2014, 38(5): 330-333. doi:10.3760/cma.j.issn.1673-5803.2014.05.009 TAN Jianwen, LAI Yifan. Ocular manifestation and treatment in Lowe syndrome[J]. International Review of Ophthalmology, 2014, 38(5): 330-333. doi:10.3760/cma.j.issn.1673-5803.2014.05.009 [18] 周新龙, 王清明, 邹姒妮, 等. 一个眼-脑-肾综合征家系的 OCRL基因变异研究[J]. 中华医学遗传学杂志, 2022, 39(1): 56-59. doi:10.3760/cma.j.cn511374-20200617-00448 ZHOU Xinlong, WANG Qingming, ZOU Sini, et al. Analysis of OCRL gene variant in a Chinese pedigree affected with Lowe syndrome[J]. Chinese Journal of Medical Genetics, 2022, 39(1): 56-59. doi:10.3760/cma.j.cn511374-20200617-00448 [19] Ma X, Ning K, Jabbehdari S, et al. Oculocerebrorenal syndrome of Lowe: survey of ophthalmic presentations and management[J]. Eur J Ophthalmol, 2020, 30(5): 966-973. doi:10.1177/1120672120920544 [20] Walton DS, Katsavounidou G, Lowe CU. Glaucoma with the oculocerebrorenal syndrome of lowe[J]. J Glaucoma, 2005, 14(3): 181-185. doi:10.1097/01.ijg.0000158850.07732.05 [21] 张辉, 谢立信. 婴幼儿先天性白内障术后继发性青光眼的临床分析[J]. 中华眼科杂志, 2013, 49(2): 134-138. doi:10.3760/cma.j.issn.0412-4081.2013.02.009 ZHANG Hui, XIE Lixin. Clinical analysis of the occurrence of secondary glaucoma after pediatric congenital cataract surgery in the first 36 months of life[J]. Chinese Journal of Ophthalmology, 2013, 49(2): 134-138. doi:10.3760/cma.j.issn.0412-4081.2013.02.009 [22] 祁锦艳, 肖伟, 王明玥, 等. 婴幼儿先天性白内障吸除术后长期疗效观察[J]. 中华眼科杂志, 2017, 53(4): 266-273. doi:10.3760/cma.j.issn.0412-4081.2017.04.008 QI Jinyan, XIAO Wei, WANG Mingyue, et al. Long-term outcomes after cataract surgery in infants with congenital cataract[J]. Chinese Journal of Ophthalmology, 2017, 53(4): 266-273. doi:10.3760/cma.j.issn.0412-4081.2017.04.008 [23] Kruger SJ, Wilson ME, Hutchinson AK, et al. Cataracts and glaucoma in patients with oculocerebrorenal syndrome[J]. Arch Ophthalmol, 2003, 121(9): 1234-1237. doi: 10.1001/archopht.121.9.1234 |
| [1] | ZHONG Yu, LIAO Zhimin, DUAN Xuanchu. Progress in the applications of XEN microstent in glaucoma surgery [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(1): 145-151. |
| [2] | SHI Boying, LIANG Hao, LI Yihong, TANG Dongyong. Surgical treatment of a cataract complicated by anti-glaucoma surgery in an adult patient with Blau syndrome [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 60-65. |
| [3] | LIU Lele, KONG XiangyunOverview,SHEN JiaquanGuidance. Progress of cyclodestructive surgeries for treating glaucoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 123-128. |
| [4] | TANG Feiran, KONG XiangyunOverview,SHEN JiaquanGuidance. Research progress in the role of OCTA in measuring superficial peripapillary vessel density in the diagnosis and treatment of glaucoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 77-82. |
| [5] | ZHAO Ying, ZHANG ShanOverview,XU Jiajun, ZHAO JingruGuidance. Research progress on the protective mechanism of heat shock protein 72 in glaucoma retinal ganglion cells [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 83-87. |
| [6] | ObjectiveTo discuss the causes and appropriate treatment for iris neovascularization following the analysis of cases( eyes). MethodsIt was a retrospective case series study involving patients( eyes)with iris neovascularization diagnosed between September and July . All the patients underwent ophthalmic examination, and all the examination findings and treatments were recorded. The causes, correlative factors, and treatment outcomes of iris neovascularization were analyzed. ResultsOf the patients, ( eyes, .%)had retinal ischemic signs, including vitreous hemorrhage and retinal vascularization on fundus fluorescein angiography, ( eyes, .%)did not have retinal ischemic signs. After months of treatment, retinal vascularization resolved in all the cases, and iris neovascularization resolved completely in patients( eyes, .%), iris neovascularization was still found in patients( eyes, .%). ConclusionsAnterior segment ischemia may also lead to iris vascularization, although retinal ischemia was the main cause. Additionally, iris neovascularization may not always resolve with treatment for retinal ischemia. Finally, anti-VEGF drug injection was an effective treatment for iris neovascularization.. Case analysis of 25 cases of iris neovascularizationLI Xuan1,2, HUANG Yingxiang2 1. Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; 2. Department of Fundus Disease and Eye Trauma, Eye Hospital China Academy of Chinese Medicine Sciences, Beijing 100040, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 41-47. |
| [7] | ObjectiveTo discuss the early diagnosis and multidisciplinary diagnosis and treatment of neovascular glaucoma in ocular ischemic syndrome. MethodsThe medical records of a 54-year-old male patient with cerebral infarction who presented with right-eye vision loss that had persisted for a week were reviewed. After slit-lamp examination and fluorescence angiography, he was diagnosed with ocular ischemic syndrome(OIS)complicated by neovascular glaucoma in the right eye and treated with intravitreal injection of anti-VEGF drugs and panretinal photocoagulation. ResultsAfter three months of treatment, the right-eye iris neovascularization subsided, and the intraocular pressure was controlled within normal limits. ConclusionOcular ischemia is often missed or misdiagnosed by ophthalmologists, neurologists, cardiologists, and vascular surgeons due to its insidious onset and complex clinical manifestations. Therefore, the establishment of multidisciplinary diagnosis and treatment can improve the prognosis of OIS patients.. Neovascular glaucoma in ocular ischemic syndrome: a case report and literature reviewQIN Shuqi1, WANG Luping1, JIANG Bin2, WANG Yanling1 1. Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 10050, China; 2. Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing 10050, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 53-55. |
| [8] | Ruibao LIU,Ying ZHAO,Minglu GUO,Yu DUAN,Yanxia WU,Xuejing LU. Autophagy and its research progress in glaucoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 158-161. |
| [9] | LIU Lin, ZHENG Hua, CHEN Shaolin, DUAN Xuanchu. Neuroprotective effects and safety of stem cell transplantation in rats with experimental glaucoma: a systematic review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 138-144. |
| [10] | TENG Xingbo, CAO Zhi, SUN Haixia, LIU Xianjin, YANGa Weizhou, ZHU Yan, ZHU Yuguang. Role of GRP94 and EIF2α in trabecular bone of primary angle-closure glaucoma patients [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 115-118. |
| [11] | XIE Hongbin, YANG Meina, CHEN Qingshan, LIU Xuyang, FAN Ning. Analysis of immunoglobulin G4-related ophthalmic disease associated with secondary glaucoma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(2): 99-102. |
| [12] | GAO Xue, HAO Linlin, LIU Shaohua, ZHANG Han. Comparison of two intraocular lens measurement formulas for prediction of postoperative refraction accuracy in patients with angle closure glaucoma and cataract [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(1): 68-71. |
| [13] | XU Xiao. Clinical observations of Ex-PRESS glaucoma filtration device implantation in patients with glaucoma. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 90-93. |
| [14] | . Efficacy and safety of EX-PRESS implanation versus trabeculectomy for open-angle glaucoma: a meta-analysis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(2): 104-111. |
| [15] | . The aqueous levels of TNF-α and IP-10 in different kinds of glaucoma and their correlation. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 103-106. |
|
||